Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Hydroxychloroquine in Patients With Hormone-Dependent Prostate-Specific Antigen (PSA) Progression After Local Therapy for Prostate Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Active	18 and over	NCI	CINJ-080803 080803, NCT00726596

Trial Description

Purpose:

Hydroxychloroquine may stop the growth of tumor cells by blocking some of the cellular functions needed for cells to survive.

This phase II trial is studying how well hydroxychloroquine works in treating patients with rising prostate-specific antigen (PSA) levels after local therapy for prostate cancer.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• No metastatic cancer
• Has undergone radiation therapy or surgery to remove the prostate
• At least 3 months since hormone ablation therapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive hydroxychloroquine by mouth once a day for up to 6 months.

After finishing treatment, patients will be evaluated for 1 year.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

Mark Stein, MD, Principal investigator		Ph: 732-235-6777

U.S.A.
New Jersey
	Hamilton
	Cancer Institute of New Jersey at Hamilton
		Clinical Trials Office - Cancer Institute of New Jersey at Hamilton	Ph:  609-631-6946
	Morristown
	Carol G. Simon Cancer Center at Morristown Memorial Hospital
		Contact Person	Ph:  973-971-6100 800-247-9580
	New Brunswick
	Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
		Clinical Trials Office - Cancer Institute of New Jersey	Ph:  732-235-8675
	Summit
	Overlook Hospital
		Contact Person	Ph:  908-522-2000

Registry Information
Official Title		NJ 1808: Autophagic Cell Death in Patients with Hormone-Dependent Prostate-Specific Antigen Progression after Local Therapy for Prostate Cancer
Trial Start Date		2008-08-12
Trial Completion Date		2011-07-07 (estimated)
Registered in ClinicalTrials.gov		NCT00726596
Date Submitted to PDQ		2008-07-14
Information Last Verified		2009-07-17
NCI Grant/Contract Number		CA72720

Back to Top